Hemispherx BioPharma, Inc. (NYSEMKT:HEB)

CAPS Rating: 1 out of 5

A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Recs

1
Player Avatar Allstar13913 (99.82) Submitted: 2/21/2007 7:06:02 PM : Underperform Start Price: $1.97 HEB Score: +77.20

Bill Mann said it best. This stock is crap. Ampligen their

Featured Broker Partners


Advertisement